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Quality assurancea b s t r a c t
Background and purpose: We performed a retrospective central review of tumour outlines in patients
undergoing radiotherapy in the SCALOP trial.
Materials and methods: The planning CT scans were reviewed retrospectively by a central review team,
and the accuracy of investigators’ GTV (iGTV) and PTV (iPTV) was compared to the trials team-defined
gold standard (gsGTV and gsPTV) using the Jaccard Conformity Index (JCI) and Geographical Miss
Index (GMI). The prognostic value of JCI and GMI was also assessed. The RT plans were also reviewed
against protocol-defined constraints.
Results: 60 patients with diagnostic-quality planning scans were included. The median whole volume JCI
for GTV was 0.64 (IQR: 0.43–0.82), and the median GMI was 0.11 (IQR: 0.05–0.22). For PTVs, the median
JCI and GMI were 0.80 (IQR: 0.71–0.88) and 0.04 (IQR: 0.02–0.12) respectively. Tumour was completely
missed in 1 patient, andP 50% of the tumour was missed in 3. Patients with JCI for GTVP 0.7 had 7.12
(95% CIs: 1.83–27.67, p = 0.005) higher odds of progressing by 9 months in multivariate analysis. Major
deviations in RT planning were noted in 4.5% of cases.
Conclusions: Radiotherapy workshops and real-time central review of contours are required in RT trials of
pancreatic cancer.
 2016 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 120 (2016) 212–216.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).In modern radiotherapy trials, a high quality Radiotherapy (RT)
Trial Quality Assurance programme (RTQA) is essential to facilitate
administration of high quality RT [1,2]. Previous studies have
reported an adverse impact of violation in RT protocol on the over-
all survival of patients [1–3].
A RTQA protocol should incorporate detailed contouring
instructions, outlining atlases and benchmark cases to provide
training to radiation oncologists and confirm their ability to exe-
cute treatment according to the protocol guidelines [4]. However,
the previous RTQA studies have largely reported pre-trial bench-
mark case outlining and plans, and on-trial reports have focused
on the quality of RT plans rather than the quality of tumour delin-
eation [4]. Quality of tumour delineation is likely to be particularlyimportant in pancreatic cancer as tumours have ill-defined mar-
gins and remain closely related to critical organs at risk (OARs),
exposing patients both to risk of geographic miss as well as normal
tissue toxicity [5].
The Selective Chemoradiotherapy (CRT) in Advanced Localized
pancreatic cancer study (SCALOP, EudraCT No: 2008-001394-1)
was a randomized phase II trial [6]. Patients were treated with
induction chemotherapy with gemcitabine/capecitabine followed
by randomization to either gemcitabine- or capecitabine-based
CRT [5]. All patients provided written informed consent and the
trial protocol was approved by the UK Medicines and Healthcare
Products Regulatory Agency (MHRA) and a multi-centre research
ethics committee. In total, 114 patients from 28 centres partici-
pated, and 74 patients received CRT. Radiation was given confor-
mally to a dose of 50.4 Gy in 28 fractions; concomitant
gemcitabine was given at a dose of 300 mg/m2 weekly, and cape-
citabine was 830 mg/m2 administered twice daily on days of RT.
We have previously reported the main trial outcome [6], and more
recently demonstrated considerable variation in GTV delineation
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gramme [7].
In the present study, we have retrospectively reviewed the indi-
vidual contours of patients entered in the trial using planning CT
scans collected prospectively during the trial, and the RT plans
were reviewed against protocol-defined constraints. The purpose
of the present work was to examine: (1) the comparison of tumour
volumes delineated by trial investigators with ‘‘gold standard”
ones re-outlined by central team; (2) the utility of Jaccard Confor-
mity Index (JCI) and Geographical Miss Index (GMI) in predicting
the primary clinical endpoint of the SCALOP1 trial; (3) the compli-
ance of the individual investigators to all aspects of dose prescrip-
tion and RT protocol.
Materials and methods
The planning CT scans of patients undergoing RT as part of SCA-
LOP trial, including contoured tumour and OAR volumes, 3D dose
cube and the Planning Assessment Form (PAF) were submitted
by the investigators to the central RTQA office. The PAF (Supple-
mentary Fig. 1) had been developed as a trial-specific, patient-
specific form where the investigators were instructed to manually
enter the dose to tumour and OAR in a given patient. The trial-
specific dose constraints were pre-printed on the PAF as aid-
memoire, to minimize the chances of protocol violation.Review of tumour outlines of the on-trial cases
The planning CT scans from all patients were reviewed by the
central team that consisted of 2 radiation oncologists with experi-
ence in pancreatic cancer RT contouring (SM, EF), including the
Chief Investigator (SM) and a radiologist with experience in pan-
creatic radiology (NP). From the total of 74 patients randomised
within the trial, the intravenous (iv) contrasted planning CT in 62
patients were considered to be of sufficient diagnostic quality to
allow re-outlining of the pancreatic tumour without the need for
further diagnostic imaging. Two of these patients died prior to
receiving any radiotherapy and so were excluded from these anal-
yses. The tumours were outlined independently, without consider-
ing the outline of the original investigator. ‘Gold standard’ set of
reference structures (gsGTV, gsPTV) were created for each patient
following assessment of and consensus for each of the contoured
on-trial cases (n = 60) by the central review team. The original
investigator defined volumes (iGTV and iPTV) were then compared
against gsGTV and gsPTV using geometric analysis [8].Geometric analysis of contours
For geometric analysis, DICOM-RT datasets from individual
patients were uploaded into the Computational Environment for
Radiotherapy Research (CERR) [9], a Matlab-based open source
application capable of processing radiotherapy treatment planning
data in DICOM2 format including volumes of interest and dose maps.
Whole volume Jaccard Conformity Index (JCI) and Geographic Miss
Index (GMI) [8] were generated for both GTV and PTV comparison
as described before [10,11]. JCI is defined as the volume of the gold
standard contour encompassed by the investigator contour as a frac-
tion of their combined volume. A JCI of 1 represents total agreement,
and JCI of 0 represents no agreement. GMI is defined as the volume
of gold standard contour missed by the investigator contour, as a
fraction of the gold standard contour. A GMI of 0 represents no miss,
whereas a GMI of 1 represents that all of the gold standard volume
has been missed by the investigator. A good investigator contour will2 Digital Imaging and Communication in Medicine homepage: http://dicom.nema.
org.have a JCI close to 1 and a GMI close to 0. These indices have been
defined further in Supplementary Table 1.Review of RT plans
The Visualization and Organization of Data for Cancer Analysis
programme (VODCA 4; Medical Software Solutions, Hagendorn,
Switzerland), a commercially available software package devel-
oped for the analysis of multicenter radiotherapy trials, was used
to centrally review the DICOM-RT planning datasets for each sub-
mitted contour [7]. We investigated the plan quality and adher-
ence to dose–volume constraints. We also examined whether
PAF was completed correctly by the participating investigators
by comparing the dose values documented in PAF with those gen-
erated from VODCA.Statistical analysis
Statistical analyses were performed with the Stata 14 SE pack-
age (StatCorp LP, College Station, Texas, USA) according to a pre-
specified analysis plan. The Shapiro–Wilk test was used to assess
normality of variables before presenting summary statistics and
correlations. The sensitivity and specificity of the GMI and JCI in
predicting the primary endpoint of the SCALOP1 trial (progression
free survival at 9 months after registration into the trial) were
assessed using ROC curves to find best cut offs and logistic regres-
sion was used to allow univariable and multivariable analysis and
calculation of odds ratios. The multivariable model included all
variables thought a priori to have prognostic value.
Results
Geometric analysis of contours
The iGTV and iPTV volumes, with the corresponding GMI and
JCI data for the n = 60 cases are shown in Fig. 1. The median vol-
umes of gsGTV and gsPTV were 28.0 cm3 (IQR: 15.7–36.2) and
256.9 cm3 (IQR: 195.0–313.4), respectively. In comparison, the
median iGTVs and iPTVs were 33.2 cm3 (IQR: 21.3–46.4) and
277.5 cm3 (IQR: 220.8–346.2), respectively. The median whole vol-
ume JCI for GTV was 0.64 (IQR: 0.43–0.82), and the median GMI
was 0.11 (IQR: 0.05–0.22). For PTVs, the median JCI was 0.80
(IQR: 0.71–0.88) and the median GMI was 0.04 (IQR: 0.02–0.12).
In one case, the iGTV GMI = 1 (implying tumour was completely
missed), and in 3 other cases, GMI was >0.5 (implying at least
50% tumour miss). We failed to observe a close correlation
between contoured volumes (iGTV, iPTV) and indices (Fig. 1).
Indeed, the Spearman’s rho calculation results were as follows:
iGTV jciGTV Spearman’s rho = 0.0714, iGTV gmiGTV Spearman’s
rho = 0.3590, iPTV jciPTV Spearman’s rho = 0.1464 and iPTV
gmiPTV Spearman’s rho = 0.4011.Relationship of geometric indices with the clinical outcome
Of the 60 patients with high quality computer tomography
imaging data, 58 had outcome data on PFS at 9 months. Fig. 2
shows the distributions of the GMI and JCI indices according to
whether or not the patients progressed by 9 months. JCI GTV has
the biggest difference in distribution between the two groups with
higher JCI values in the group who progressed. ROC curves for GMIs
and JCIs for PTVs and GTVs are shown in Supplementary Fig. 2.
Only JCI PTV and GTV produced ROC curves with AUC > 0.6 and
these had cut offs of 0.8 and 0.7 respectively providing the most
correct classifications (60.34% and 70.69% respectively).
Table 1 shows the results of univariable and multivariable logis-
tic regression for 9-month PFS. Of JCI GTV and PTV, JCI GTV showed
Fig. 1. Scatter plot showing the correlation of the Geographical Miss Index (GMI)
and the Jaccard Conformity Index (JCI) with (A) the investigator gross tumour
volumes (iGTVs) and (B) the investigator planning target volumes (iPTVs).
Fig. 2. Distributions of the JCI and GMI indices by progression status at 9 months.
214 Assessing on-trial contours in the SCALOP trialthe best univariable potential (p = 0.003) and was taken forward
into the multivariable model where there continued to be strong
evidence of its prognostic value. Patients with JCI GTVP 0.7
(implying at least 70% agreement between investigator and gold
standard volume) had a 7.12 (95% CIs: 1.83–27.67, p = 0.005)
higher odds of progressing by 9 months than those patients with
JCI < 0.7.Review of PAF
Of the 74 planned patients, self-reported PAF was available for
70 and CD ROMs were submitted for 72, but the full DICOM data(CT slices, structures and dose) could only be processed and anal-
ysed in 66 cases. In general, there was good compliance to all
aspects of dose prescription to PTV although deviations were
observed (Table 2). Indeed, there were 7 minor deviations in
the PTV receiving 95% of the prescribed dose falling below the
required 99% with a minimum of 95.3%. PTV Dmin was recorded
on the PAF as between 90% and 93% for 10 patients (minor devi-
ations) and <90% for 3 patients (major deviations, 4.5%). There
was one minor deviation for the ICRU maximum defined dose
of 107.9%. We failed to observe any deviation in the prescribed
dose to the OARs.
Furthermore, we imported the planning values into VODCA
and compared them to the PAF for the 66 cases to assess the
accuracy of PAF completion and adherence to dose–volume con-
straints by the investigators (Fig. 3A–F). Seven minor deviations
of dose constraints were identified from the PAF for PTV D95
(<99%), whereas one minor regarding the ICRU max (value
107.8). For the ipsilateral kidney receiving 20 Gy, seven minor
deviations were found and incorrect identification of the ipsilat-
eral kidney occurred in two cases (major deviations, 3%), which
is significantly improved compared to the pre-trial case (20%)
[7]. Other minor discrepancies were noted between PAF and
VODCA regarding the maximum dose to the spinal cord (n = 7),
combined kidney receiving 20 Gy (n = 15), PTV volume (n = 2)
and liver receiving 30 Gy (n = 1).Discussion
In the present study we report the on-trial RTQA from the SCA-
LOP trial. The median whole volume JCI for GTV was 0.64 (IQR:
0.43–0.82), and the median GMI was 0.11 (IQR: 0.05–0.22). For
PTVs, the median JCI was 0.80 (IQR: 0.71–0.88) and the median
GMI was 0.04 (IQR: 0.02–0.12). This appears to be consistent with
the data shown in the recently reported pre-trial study [7]. In one
case, the tumour was completely missed (GTV GMI = 1) and in 3
other cases, GMI was >0.5 (implying at least 50% tumour miss).
No errors in GTV to PTV expansion were identified, and during
treatment planning and delivery, incidence of major deviations
were low.
The data recorded on the PAF were highly concordant with the
actual planning data with no major discrepancies, suggesting that
PAF could be used as a simple and effective aide- memoire to
enhance protocol compliance.
We have recently reported the pre-trial RTQA of SCALOP where
investigator contours of a test case were reviewed both quantita-
tively using geometric indices, and qualitatively (to subjectively
evaluate acceptable/unacceptable over- and under-contouring)
[7]. For contours that were considered qualitatively acceptable
for the trial, the median whole tumour GMI and JCI were 0.3
(IQR 0.15–0.4) and 0.75 (IQR 0.7–0.8), respectively. The median
geometric indices for GTV and PTV seen in on-trial patients were
better than the test case, suggesting that overall, quality of tumour
delineation was acceptable and that the pre-trial RTQA may have
enhanced the quality of tumour delineation within the main trial.
However, 4 cases had a tumour GMI in excess of 0.5, of which, the
entire tumour was missed in one case – this suggests that although
pre-trial RTQA can enhance the overall quality of tumour delin-
eation, on-trial, real-time, central review is still necessary to
ensure that the highest quality in tumour delineation is
maintained.
Although retrospective, this is the first review of on-trial RTQA
data from a clinical trial in LAPC and provides insight into the
potential benefit of prospective review in this clinical setting.
Experience from other setting/other tumour sites suggests that
on-trial QA is essential to maintain integrity and quality of radia-
Table 1
Univariable and multivariable logistic regression of potential prognostic factors for disease progression by 9 months.
Univariable analysis Multivariable analysis
n Odds ratio 95% CIs p n Odds ratio 95% CIs p
gsGTV continuous 58 1.02 0.98–1.05 0.341 58 0.99 0.96–1.04 0.876
JCI GTV <0.7 32 1.00 32 1.00
P0.7 26 5.71 1.81–18.08 0.003 26 7.43 1.86–29.7 0.005
JCI PTV <0.8 28 1.00
P0.8 30 2.5 0.84–7.42 0.099
Trial arm Gem 35 1.00 27 1.00
Cape 35 0.63 0.24–1.62 0.335 31 0.57 0.15-2.21 0.417
WHO PS 0 29 1.00 24 1.00
1–2 41 1.41 0.54–3.73 0.484 34 1.45 0.39–5.43 0.583
Sex Male 40 1.00 34 1.00
Female 30 2.12 0.81–5.59 0.127 24 2.94 0.77–11.21 0.113
Age <65 36 1.00 30 1.00
P65 34 0.55 0.21–1.42 0.216 28 1.43 0.33–6.11 0.632
RT fractions 0–26 12 1.00 10 1.00
27+ 50 0.47 0.13–1.66 0.240 48 0.57 0.11–3.03 0.508
Table 2
Dose to PTV and OARs reported on the self-reported PAF.
Structure Constraint Mean SD Min Max Minor deviations Major deviations
PTV vol (cc) N/A 299.8 113.4 61.3 600.2 N/A N/A
PTV D95 (%) >99% 99.4 1.13 95.3 100 7 None
PTV Dmin minimum (%) N/A 93.9 1.70 86.7 96.4 10 below 93% 3 below 90%
ICRU max dose (%) 107% 103.8 1.90 100 107.9 1 None
Liver V30 (%) <40% 12.6 8.2 0 30.3 None None
Ipsilateral kidney V20 (%) <40% 10.6 10.5 0 36.2 None None
Combined kidney V20 (%) <30% 6.5 6.8 0 24 None None
Spinal cord PRV Dmax (Gy) <40 Gy 21.5 7.2 8.7 39.3 None None
Abbreviations: N/A, not applicable; ICRU, International Commission on Radiation Units; SD, standard deviation.
Fig. 3. Illustration of the relationship between on-trial planning assessment form (PAF) value and the Visualization and Organization of Data for Cancer Analysis programme
(VODCA) values in n = 66 cases, as indicated (A–F). Minor deviations are shown with black squares. Incorrect identification of the ipsilateral kidney (C) occurred in two cases
(shown with circle).
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operative tumour bed delineation was demonstrated in RTOG
9704, an adjuvant trial in pancreatic cancer, which also demon-
strated a survival detriment in patients with major protocol viola-
tions [1]. In the recently reported NEOSCOPE study in oesophagealcancer, 86 patients were randomized to 2 pre-operative chemora-
diation regimens. Eighty-three contours were reviewed, 39 (47%)
of whom were reviewed prior to start of treatment and 44 (53%)
were reviewed in a timely retrospective manner (prior to third
fraction of RT). Nine cases (11%) required re-submission – inappro-
216 Assessing on-trial contours in the SCALOP trialpriate delineation of GTV and elective regional nodes were the
most common cause of unacceptable deviations [12]. A recent
study of brain metastasis has also demonstrated that real-time
pre-treatment review of investigator contours and treatment plan-
ning limit unacceptable deviations [13]. Eighty-seven of 113
patients entered in the study underwent pre-treatment review.
Twenty-one (24%) were noted to have unacceptable deviation, 18
of which were corrected on 2nd attempt and 2 on third attempt.
Further 22 cases were reviewed retrospectively – 23% were found
to have unacceptable deviations.
Prospective on-trial RTQA is a resource intensive, time-
consuming and onerous process. On one hand – particularly in
complex technical radiation trials (e.g. SBRT) or radiation with
novel drug combination trials – there is risk of patient harm if
appropriate radiotherapy is not undertaken; on the other hand,
the RTQA process itself may unacceptably delay patient manage-
ment. There are two potential options to achieve the best balance,
either (a) to limit the trial to high volume centres to minimize the
risk, or (b) undertake prospective review on a limited number of
patients per centre, followed by timely retrospective or random
reviews of subsequent cases. There are some data to support the
former option from a non-pancreatic cancer clinical trial – the
RTQA from one multi-centre Japanese study in oesophageal cancer
(n = 142) shows that all unacceptable violations were from insti-
tutes which enrolled <7 patients [14].
Finally, we noted a strong relationship between JCI and survival,
which remained as a highly significant independent prognostic
marker on multivariate analysis even after adjusting for confound-
ing variables, including tumour size. However, the optimum prog-
nostic cut off of 0.7 that we found in this study would need to be
validated in future studies. At this stage, we are unable to provide
a suitable explanation why a high concordance between investiga-
tor and gold-standard contours predict for worse outcome – this
observation that was counterintuitive to our expectations that
lower JCI (ie a lower concordance) would predict worse survival.
Of note, patients with higher JCI appeared to have significantly lar-
ger GTV compared to patients with lower JCI, albeit GTV lacked
correlation with the 9-month PFS. A plausible hypothesis could
be that better demarcated tumours (where there is likely to be a
higher agreement amongst investigators, therefore higher JCI val-
ues) may reflect a more aggressive disease with worse prognosis.
It is also possible that in patients who responded to the induction
chemotherapy (and therefore had better prognosis), the tumour
margins became less discernable leading to greater variation in
contour delineation between the original investigator and review
team. We are planning to pursue this issue in depth in the future
through analysis of the correlation between CT image texture
and clinical outcome.
The main limitation of this study was the unavailability of diag-
nostic images while performing central review, as diagnostic
images were not routinely collected as part of this trial. It is possi-
ble that the discrepancies in outlines between the investigator and
the review team may have been due to lack of adequate diagnostic
information at the time of central review. However, the JCI and
GMI values were similar or better than that seen at pre-trial test
case, suggesting that this is unlikely to be the case.
In summary, the present study based on the SCALOP cohort
highlights the need for on-trial prospective QA in future radia-
tion trials in pancreatic cancer. PAF appears to be a simple tool
to minimize protocol violation by providing an aide-memoire to
protocol constraints and correlated well with the actual dose
distribution. The relationship between JCI and survival shown
needs to be explored further. Future trials are expected to ben-
efit from the implementation of similar RTQA programmes that
should include educational RT courses and real-time central
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